Skip to content

Supplier News

Heineken kicks off “Summer of Soccer”

Heineken kicks off “Summer of Soccer”

Heineken today kicks off its “Summer of Soccer” campaign as a worldwide leader and supporter of the sport. Soccer has been a central platform for Heineken globally for decades, and the brand’s recently launched U.S.

Dr. Reddy’s rolls out generic of Plaquenil

Dr. Reddy’s rolls out generic of Plaquenil

Dr. Reddy’s Laboratories announced the launch of hydroxychloroquine sulfate tablets USP, 200 mg, a therapeutic equivalent generic version of Plaquenil (hydroxychloroquine sulfate) tablets, in the U.S. market, approved by the U.S. Food and Drug Administration. The Plaquenil brand and generic had U.S.

Hyland’s expands commitment to sport cycling

Hyland’s expands commitment to sport cycling

LOS ANGELES – Homeopathic medicine supplier Hyland’s Inc. is continuing its advertorial relationship with NBC and the Tour de France in 2018. The partnership allows Hyland’s to leverage NBC’s extensive network to connect with cyclists on the world’s biggest stage.

New Voices Fund rolls out during 2018 Essence Festival

New Voices Fund rolls out during 2018 Essence Festival

NEW YORK – The $100 million New Voices Fund, the next-generation fund set up to make private equity investments in businesses owned and/or managed by women of color, officially launched today at the 2018 Essence Festival in New Orleans.

Catalent agrees to buy Juniper Pharmaceuticals

Catalent agrees to buy Juniper Pharmaceuticals

SOMERSET, N.J. – Catalent, a leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products,  announced that it has agreed to acquire Juniper Pharmaceuticals, including its Nottingham, U.K.-based Juniper Pharma Services division.

FDA approves Xeomin for adult patients with sialorrhea

FDA approves Xeomin for adult patients with sialorrhea

Merz North America announced  that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Xeomin (incobotulinumtoxinA) for the treatment of chronic sialorrhea, or excessive drooling, in adult patients.